| Literature DB >> 25582691 |
Elizabeth Hazel, Agbessi Amouzou, Lois Park, Benjamin Banda, Tiyese Chimuna, Tanya Guenther, Humphreys Nsona, Cesar G Victora, Jennifer Bryce.
Abstract
Health surveillance assistants (HSAs) in Malawi have provided community case management (CCM) since 2008; however, program monitoring remains challenging. Mobile technology holds the potential to improve data, but rigorous assessments are few. This study tested the validity of collecting CCM implementation strength indicators through mobile phone interviews with HSAs. This validation study compared mobile phone interviews with information obtained through inspection visits. Sensitivity and specificity were measured to determine validity. Using mobile phones to interview HSAs on CCM implementation strength indicators produces accurate information. For deployment, training, and medicine stocks, the specificity and sensitivity of the results were excellent (> 90%). The sensitivity and specificity of this method for drug stock-outs, supervision, and mentoring were lower but with a few exceptions, still above 80%. This study provided a rigorous assessment of the accuracy of implementation strength data collected through mobile technologies and is an important step forward for evaluation of public health programs. © The American Society of Tropical Medicine and Hygiene.Entities:
Mesh:
Year: 2015 PMID: 25582691 PMCID: PMC4350569 DOI: 10.4269/ajtmh.14-0396
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 2.345
Description of the study validation methods
| Implementation strength indicator | Validation method | Description |
|---|---|---|
| Validation at the health center/supervisor level | ||
| (1) Percentage of HSAs currently working | Supervisor records | Record review; if no record was available, supervisor responded from memory |
| (2) Percentage of HSAs trained in CCM | Supervisor records | |
| (3) Percentage of HSAs supervised in the previous 3 months | Supervisor records and monthly monitoring form | Record review; if no record was available, supervisor responded from memory |
| (4) Percentage of HSAs who received clinical mentoring in the previous 3 months | ||
| (5) Percentage of HSAs supervised with reinforcement of clinical practice for the most recent supervision in the previous 3 months | Supervision and mentoring checklists | Review of most recent completed checklist; if no checklist was available, information was not captured |
| (6) Percentage of HSAs with a drug stock-out in the previous 3 reporting months | Monthly monitoring form review | Review of six most recent monthly monitoring forms; if all six were not accessible, then data were recorded from the partial set |
| Validation at the village clinic/HSA level | ||
| (8) Percentage of HSAs with current stocks of CCM drugs/supplies | Observation at VC | Direct observation of drugs/supplies at HSA VC |
| (9) Percentage of HSAs with minimum stocks of CCM drugs | ||
| (10) Percentage of HSAs who have treated a sick child in the previous 3 months | Register review | Direct observation of CCM register at HSA VC |
VC = village clinic.
HSAs were asked only about the stock-outs that had been reported to the health center through the monitoring form so that the information could be validated. It did not include recent stock-outs.
Figure 1.Health centers and the CCM-trained HSA population, selection and interviewed/data collected.
Implementation strength indicators reported by the HSA versus observed by the interviewers with sensitivity and specificity of the HSA cellphone interview method (weighted)
| Implementation strength indicator | Reported percentage ( | Observed percentage ( | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|
| HSAs working at the time of the assessment | 100 (200/200) | 100 (200/200) | 100 | 100 |
| HSAs trained in CCM | 99 (199/200) | 100 (200/200) | 99 | 100 |
| HSAs who received drug box | 100 (200/200) | 100 (200/200) | 100 | 100 |
| HSAs who have seen a sick child in the past 7 days | 89 (178/200) | 89 (177/200) | 100 | 97 |
| Average (range) number of children treated in the previous 7 days | 11.2 (0–58) | 10.8 (0–54) | Bland–Altman mean difference | |
| HSAs supervised in CCM in the last 3 months | 30 (60/200) | 30 (60/200) | 80 | 91 |
| HSAs mentored in CCM in the last 3 months | 29 (57/200) | 19 (37/200) | 84 | 84 |
| HSAs supervised with reinforcement of clinical practice for most recent supervision | 41 (82/199) | 35 (69/199) | 87 | 83 |
| HSAs with current stocks | ||||
| LA 1 × 6 | 87 (171/198) | 86 (170/198) | 100 | 95 |
| LA 2 × 6 | 86 (171/198) | 87 (172/198) | 99 | 98 |
| Cotrimoxazole | 85 (169/198) | 85 (168/198) | 99 | 94 |
| ORS | 83 (164/198) | 82 (163/198) | 100 | 96 |
| Zinc | 81 (160/198) | 81 (160/198) | 100 | 100 |
| All drugs | 60 (118/198) | 59 (116/198) | 100 | 98 |
| HSAs with no stock-out in the previous 3 reporting months | ||||
| LA 1 × 6 | 87 (78/89) | 88 (78/89) | 94 | 59 |
| LA 2 × 6 | 84 (75/89) | 82 (73/89) | 94 | 60 |
| Cotrimoxazole | 90 (80/89) | 89 (80/89) | 100 | 94 |
| ORS | 82 (73/89) | 84 (75/89) | 97 | 100 |
| Zinc | 80 (71/89) | 85 (76/89) | 92 | 90 |
| All drugs | 58 (52/89) | 65 (58/89) | 89 | 100 |
| HSAs with minimum stocks | ||||
| LA 1 × 6 (six blister packs/36 tablets) | 82 (163/199) | 82 (163/199) | 100 | 98 |
| LA 2 × 6 (four blister packs/48 tablets) | 83 (165/199) | 83 (165/199) | 100 | 98 |
| Cotrimoxazole (60 tablets) | 83 (165/199) | 83 (165/199) | 100 | 100 |
| ORS (12 sachets) | 69 (138/199) | 70 (139/199) | 99 | 100 |
| Zinc (60 tablets) | 67 (133/199) | 67 (134/199) | 98 | 98 |
| All drugs | 49 (97/199) | 50 (99/199) | 97 | 99 |
| HSAs with CCM supplies | ||||
| Timer | 97 (195/200) | 97 (195/200) | 100 | 82 |
| MUAC | 96 (192/200) | 96 (191/200) | 100 | 91 |
| Sick Child Recording Form | 97 (194/199) | 97 (192/199) | 99 | 67 |
| Sick Child | 100 (198/199) | 100 (199/199) | 100 | 100 |
CI = confidence interval; MUAC = mid-upper arm circumference.
The Bland–Altman test does not take into account the clustered nature of the data because of specifications of the software; however, taking clustering into account tends to increase confidence intervals so that the present non-significant result is unlikely to change had the clustering been taken into account.
Excluded any HSAs with missing or inconsistent data.
Included only HSAs with a full set of Forms 1A at the health center to perform the validation.